CC BY 4.0 · SynOpen 2024; 08(03): 130-137
DOI: 10.1055/s-0043-1775378
paper

Functionalization of Position 7 of Pyrazolo[1,5-a]pyrazines

Georgyi Koidan
a   Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Academician Kukhar str., 5, Kyiv-94, 02660, Ukraine
,
Nazar Tsyzoryk
a   Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Academician Kukhar str., 5, Kyiv-94, 02660, Ukraine
,
Eduard B. Rusanov
a   Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Academician Kukhar str., 5, Kyiv-94, 02660, Ukraine
,
Svitlana V. Shishkina
b   SSI Institute for Single Crystals, Nauki ave. 60, 61001 Kharkiv-01, Ukraine
,
Mykhailo Vovk
a   Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Academician Kukhar str., 5, Kyiv-94, 02660, Ukraine
,
a   Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Academician Kukhar str., 5, Kyiv-94, 02660, Ukraine
› Author Affiliations
We gratefully acknowledge the National Research Foundation of Ukraine (No. 2020.02/0105) for financial support.
 


Abstract

We report a straightforward formylation at position 7 of pyrazolo[1,5-a]pyrazine derivatives featuring substituents at the 2,3,4 positions. N,N,N′,1,1,1-Hexamethylsilanecarboximidamide exists in equilibrium with its carbene form due to 1,2-migration of the silyl group. The ensuing carbene can be inserted into the most acidic C–H group of the pyrazolo[1,5-a]pyrazines. The most acidic calculated pK a (DMSO) C–H group is at position 7 and does not depend significantly on the substituents. The reactions proceed in high yields affording aminals that can be hydrolyzed to the corresponding aldehydes. Methanolysis of the aminals affords the corresponding methylimines. The constitution of the aminals was unambiguously proved by X-ray crystal structure analysis of a set of derivatives. The method is simple, often does not require even solvents, and can be extended to other heterocyclic compounds.


#

Pyrazolo[1,5-a]pyrazines are representatives of an important class of heterocyclic systems with powerful synthetic and biological potential.[1] In recent years, systematic studies have identified many of its derivatives as inhibitors of several types of kinases,[2] [3] [4] [5] dopamine receptor agonists,[6] antagonists of vasopressin V1b,[7] fibrinogen,[8] chemokine CXCR7,[9] and orexin[10] receptors. Modern approaches to new pharmacologically promising compounds based on the pyrazolo[1,5-a]pyrazine scaffold are limited to modification of the pyrazine ring, in particular at positions 4 and 5 of the heterocyclic core.[11] [12] [13] [14] To our knowledge, there have been no previous attempts at functionalization at position 7 of the pyrazolo[1,5-a]pyrazine ring, which would contribute to a significant expansion of the chemical space of compounds for biomedical research. We have recently shown that N,N,N′,1,1,1-hexamethylsilane-carboximidamide 1 exists in equilibrium with its carbene form 1′ (Scheme [1]). Although the carbene form was not detected even spectroscopically, compound 1 behaves like a highly active nucleophilic carbene. Thus, we have shown that it inserts into sp-, sp2-, and sp3 C–H bonds, affording the corresponding aminals.[15] We have also elucidated the mechanism of the insertion reaction. On a set of benzene and pyridine derivatives, it was shown that the first step of the reaction is deprotonation of the most acidic C–H hydrogen, resulting in the formation of a tight ion pair of a formamidinium cation and a substrate anion that combine to form the final insertion product. We have extended the reaction to thiophene derivatives and demonstrated that this very simple approach can be used to prepare aldehydes of different types of heterocycles. Additionally, we have evaluated an approximate pK a range of a C–H group that could potentially react with silylformamidine 1. Silylformamidine is not commercially available at present; however, within laboratory settings, it can be synthesized in two steps on a 100-g scale, starting from trimethylformamidine and trimethylsilyl triflate, followed by deprotonation using hexamethylsilazanide lithium. It exhibits considerable stability, facilitating long-term storage. Furthermore, it demonstrates versatility in its tolerance towards numerous functional groups. Notably, it exhibits vigorous reactivity towards highly acidic functional groups containing a heteroatom–hydrogen moiety.[15]

Zoom Image
Scheme 1 N,N,N′,1,1,1-Hexamethylsilane-carboximidamide in equilibrium with the carbene form

Determination of C–H acidity of aromatic and heteroaromatic compounds is not an easy task to perform, but recently a program (https://pka.allchemy.net ) was developed and offered free that can promptly evaluate the pK a of any organic compound with accuracy of 2 units. In this way, one can relatively easily estimate the most acidic position in the molecule and predict whether it will react with silylformamidine.

Zoom Image
Figure 1 pK a values calculated for compounds 2ad in DMSO

As the introduction of a substituent can alter the pK a of a molecule markedly, we decided to study whether pyrazolo[1,5-a]pyrazine derivatives will be suitable substrates for the reaction with silylformamidine. We calculated the pK a values of all our available substrates using the freely available software at https://pka.allchemy.net in DMSO, CH3CN and THF;[16] these data are given in Table S1. For further use, we considered pK a values calculated in DMSO. Thus, for 4-substituted derivatives 2ad the calculations show that the most acidic C–H group is located at the 7-position. It is also clear that substituents affect pK a, with electron-donating substituents increasing pK a and electron-accepting substituents decreasing it (Figure [1]).

Synthesis of the Starting Compounds

Compounds 2a, 2c, 2d, and 2j were prepared according to a reported procedure.[17] Compound 2b was synthesized by nucleophilic substitution of 4-chloropyrazolo[1,5-a]pyrazine 2a with sodium methoxide. Compounds 2f and 2g were obtained starting from methyl carboxylate 2c by bromination with N-bromosuccinimide (NBS) and nitration, respectively. Polyhalogenated derivative 2i was produced by iodination of 2-bromo-4-chloropyrazolo[1,5-a]pyrazine (2j) (Scheme [2]). Compounds 2e and 2h were purchased (Enamine Ltd.) and used as received.

Zoom Image
Scheme 2 Synthesis of the starting compounds 2

We started our investigation by mixing 4-chloropyrazolo[1,5-a]pyrazine 2a with silylformamidine 1 (1.5 equiv) without solvent and, after stirring at room temperature for 4 days, the reaction proceeded cleanly to afford the target product in over 90% yield by insertion of the carbene into the C–H bond (Table [1], entry 1). We then found that it is possible to carry out the reaction at elevated temperature 70–90 °C for a shorter time (10 h). On going to 4-methoxypyrazolo[1,5-a]pyrazine 2b, it was found that the reaction proceeded only on heating the reaction mixture. Heating the reagents for 2 days at 70 °C afforded aminal 3c in 58% yield (entry 3). Electron-accepting substituents increased the rate of the reaction. Thus, 4-methoxycarbonyl derivative 2c reacted with silylformamidine 1 at 90 °C for 30 min giving aminal 3c in 71% yield (entry 4). Additionally, 4-cyano derivative 2d reacted at room temperature in 50% yield (entry 5). Thus, it is clear that electron-accepting substituents promote the insertion reaction. 4-Substituted pyrazolo[1,5-a]pyrazine derivatives are readily reacted at the 3-position via electrophilic substitution reaction so that these compounds are easily accessible. Thus, we further studied 3-substituted methyl pyrazolo[1,5-a]pyrazine-4-carboxylates 2eh. Additional electron-withdrawing substituents at the heterocyclic core further facilitated the insertion reaction (Scheme [3]).

Table 1 The Reaction of Pyrazolo[1,5-a]pyrazine Derivatives 2 with Silylformamidine 1

Entry

Compd

R

R′

R′′

Reaction conditions for 3

Yield of aminal 3 (%)

Reaction conditions for 4

Yield of aldehyde 4 (%)

1

2a

H

H

Cl

1 (1.5 equiv), r.t., 4 days

93

aminal (3 mmol), aq. HCl (15%; 2 mL), 60 °С, 10 min

93

2

4a

H

H

OH

3

2b

H

H

OMe

1 (2 equiv), 70 °C, 2 days

58

4

2c

H

H

CO2Me

1 (2 equiv), 90 °C, 30 min

71

as for 3a

83

5

2d

H

H

CN

1 (2 equiv), r.t., 20 h

50

6

2e

H

CHF2

CO2Me

1 (3 equiv), 60 °C, 15 min

88

as for 3a

87

7

2f

H

Br

CO2Me

1 (3 equiv), r.t., 20 h

90

aminal (3 mmol), aq. HBr (20%; 2 mL), 60 °С, 10 min

52

8

2g

H

NO2

CO2Me

1 (3 equiv), benzene, r.t., 30 min then 50 °C, 10 min

77

as for 3a

80

9

2h

H

CO2Me

CO2Me

1 (3 equiv), r.t., 24 h

71

as for 3a

51

10

2i

Br

I

Cl

1 (3 equiv), 80 °C, 5 min

82

Zoom Image
Scheme 3 Synthesis of imines 5 and hydrazone 6a

These compounds reacted either upon short-term heating or after a longer period at room temperature. We failed to isolate aminal 3f in analytically pure form, so this was used for further transformation without any purification. Polyhalogen substituted compound 3i reacted readily and was isolated in high yield (entry 10).

As the aminals are typically produced from aldehydes, we attempted to hydrolyse them to give the corresponding aldehydes. Hydrolysis of aminal 3a was accompanied by nucleophilic substitution of chloride with water to afford aldehyde 4a.

Hydrolysis of aminals 3 proceeded quite well, affording the corresponding aldehydes in high yield (Table [1]). Hydrolysis of aminals 3b, 3d, and 3i afforded intractable mixtures from which we failed to isolate any individual compounds. Likely, these compounds are too active and undergo side reactions during hydrolysis. Aldehydes 4c and 4e are poorly soluble in CDCl3 so NMR spectra were recorded in DMSO-d 6. Both compounds are present in two forms: the aldehyde itself and its hydrated form. Addition of water to DMSO solution almost completely shifted the equilibrium to the hydrated form (see the Supporting Information). NMR spectra of aldehydes 4f, 4g, and 4h recorded in CDCl3 exhibited exclusively peaks from the aldehyde form. Previously we showed that aminals of type 3 undergo methanolysis to afford the corresponding methylimines. Thus, we carried out methanolysis of aminals 3b and 3i (compounds with which we failed to prepare aldehydes). Additionally, methanolysis was performed for aminal 3g, which gave the corresponding aldehyde. In all cases, methanolysis afforded the corresponding methylimines 5b, 5g, and 5i in good yield.

In order to establish unambiguously the position at which the insertion occurred, the molecular structure of compounds 3f and 3g were determined by single-crystal X-ray diffraction. As we failed to grow crystals for aminal 3a or aldehyde 4a, we prepared its phenylhydrazone derivative 6a, which gave good-quality single crystals. The X-ray studies confirmed that the insertion occurred at the 7-position in all cases (Figure [2]). As depicted in Figure [1], the introduction of substituents at the heterocyclic core significantly influences the pK a of C–H groups. In compound 2a, calculations indicate an identical pK a value of 33 for positions 3 and 7. However, in our experiments, we observed solely the insertion at position 7, with no detectable traces of other regioisomers. Compound 6a exists as an NH tautomer in the crystal phase. This fact was confirmed by the determination of the hydrogen atom at the N1 atom from electron density difference maps and the length of the C1–O1 bond (1.240(4) Å), which is close to the mean value of the C=O bond (1.210 Å) (Figure [2]). Some elongation of the carbonyl bond is due to its participation in the N5–H···O1′ intermolecular hydrogen bond (symmetry operation is 0.5+x, 0.5+y, 0.5–z; H···O distance is 2.04 Å, N–H···O angle is 165°).

Zoom Image
Figure 2 Molecular structure of 3f (left), 3g (middle), and 6a (right) according to X-ray diffraction data. Thermal ellipsoids are shown at 50% probability level

In conclusion, we have devised a straightforward method to formylate substituted pyrazolo[1,5-a]pyrazines at the 7-position. Considering the ready availability of the starting pyrazolo[1,5-a]pyrazines, the high yields of the reaction, and tolerance to various substituents, we are convinced that it is a convenient and short approach to previously unknown compounds.

All solvents were purified according to the standard procedures.

1H and 13C NMR spectra were recorded with a Bruker 170 Avance 500 spectrometer (500 MHz for 1H NMR, 126 MHz for 13C NMR) and a Varian Unity Plus 400 spectrometer (400 MHz for 1H NMR, 101 MHz for 13C NMR). NMR chemical shifts are reported in ppm (δ scale) and are referenced using residual NMR solvent peaks at δ = 7.26 and 77.16 ppm for 1H and 13C in CDCl3, and at δ = 7.16 (1H), 128.0 (13C) in C6D6, respectively. Elemental analyses were performed at the Laboratory of Organic Analysis. Mass spectra were recorded with an Agilent 1100 LCMSD SL instrument (chemical ionization (CI)) and Agilent 5890 Series II 5972 MS instrument (electron impact ionization (EI)). High-resolution mass spectra (HRMS) were obtained with an Agilent 1260 Infinity UHPLC instrument coupled with an Agilent 6224 Accurate Mass TOF mass spectrometer.


#

4-Methoxypyrazolo[1,5-a]pyrazine (2b)

4-Chloropyrazolo[1,5-a]pyrazine 2a (1.54 g, 0.01 mol) was dissolved in a sodium methylate solution prepared by dissolving sodium (0.46 g, 20 mmol) in anhydrous MeOH (20 mL), then the reaction mixture was stirred at r.t. for 4 h. An aqueous 20% solution of ammonium chloride was added and MeOH was evaporated under reduced pressure. The aqueous residue was extracted with dichloromethane (2 × 10 mL). All volatiles were then evaporated and the residue was sublimated (0.1 Torr, oil bath temperature 90 °C) to afford 2b.

Yield: 93% (1.39 g); white solid; mp 85–86 °C.

1H NMR (400 MHz, CDCl3): δ = 8.0 (d, J = 5 Hz, 1 H), 7.9 (d, J = 2 Hz, 1 H), 7.32 (d, J = 5 Hz, 1 H), 6.75 (s, 1 H), 4.08 (s, 3 H).

13C NMR (100 MHz, CDCl3): δ = 157.0, 140.9, 128.5, 125.7, 117.1, 98.2, 53.8.

Anal. Calcd for C7H7N3O: C, 56.37; H, 4.73; N, 28.17. Found: C, 56.54; H, 5.15; N, 27.96.


#

Methyl 3-Bromopyrazolo[1,5-a]pyrazine-4-carboxylate (2f)

To a solution of N-bromosuccinimide (NBS) (1.06 g, 5.9 mmol) in anhydrous MeCN (50 mL) at r.t., methyl pyrazolo[1,5-a]pyrazine-4-carboxylate 2c (1 g, 5.6 mmol) was added. The reaction mixture was stirred for 3 h then the solvent was evaporated. Water (50 mL) was added to the solid residue, and the resulting mixture was filtered off, washed successively with water (25 mL) and methyl tert-butyl ether (20 mL), and dried in air.

Yield: 93% (1.34 g); yellow powder; mp 88 °C.

1H NMR (400 MHz, DMSO-d 6): δ = 9.01 (d, J =4.4 Hz, 1 H, H-7), 8.45 (s, 1 H, H-2), 8.04 (d, J =4.4 Hz, 1 H, H-6), 4.01 (s, 3 H, OCH3).

13C NMR (100 MHz, DMSO-d 6): δ = 164.0, 144.8, 144.6, 130.1, 129.2, 125.2, 86.2, 53.6.

MS: m/z (%) = 257 (100) [M + H]+.

IR: 1680, 1725 (C=O), 3346 (NH) cm–1.

Anal. Calcd for С8H6BrN3O2: C, 37.53; H, 2.36; N, 16.41. Found: C, 37.80; H, 2.25; N, 16.18.


#

Methyl 3-Nitropyrazolo[1,5-a]pyrazine-4-carboxylate (2g)

To a solution of methyl pyrazolo[1,5-a]pyrazine-4-carboxylate 2c (1 g, 5.6 mmol) in H2SO4 (10 mL) at 0 °C, HNO3 (2 mL) was added dropwise. The reaction mixture was stirred overnight at r.t. then poured onto ice and the resulting mixture was filtered off, washed with cold water (10 mL), and dried in vacuo.

Yield: 90% (1.12 g); yellow powder; mp 185 °C.

1H NMR (400 MHz, DMSO-d 6): δ = 9.29 (d, J = 4.2 Hz, 1 H, H-7), 9.18 (s, 1 H, H-2), 8.45 (d, J = 4.2 Hz, 1 H, H-6), 3.97 (s, 3 H, OCH3).

13C NMR (100 MHz, DMSO-d 6): δ = 164.3, 145.2, 142.1, 133.1, 126.8, 126.3, 125.2, 53.7.

MS: m/z (%) = 223 (100) [M + H]+.

IR: 1680, 1725 (C=O), 3346 (NH) cm–1.

Anal. Calcd for С8H6N4O4: C, 43.25; H, 2.72; N, 25.22. Found: C, 43.12; H 2.69; N, 25.44.


#

2-Bromo-4-chloro-3-iodopyrazolo[1,5-a]pyrazine (2i)

To a solution of N-iodosuccinimide (1.02 g, 4.52 mmol) in anhydrous MeCN (50 mL) at r.t., 2-bromo-4-chloropyrazolo[1,5-a]pyrazine 2j (1 g, 4.3 mmol) was added. The reaction mixture was heated at reflux for 4 h, the solvent was evaporated, water (50 mL) was added to the solid residue, and the resulting mixture was filtered off, washed with water (30 mL), Et2O (20 mL), and dried in air.

Yield: 83% (1.28 g); white powder; mp 140 °C.

1H NMR (400 MHz, DMSO-d 6): δ = 8.91 (d, J =4.8 Hz, 1 H, H-7), 7.81 (d, J = 4.8 Hz, 1 H, H-6).

13C NMR (100 MHz, DMSO-d 6): δ = 142.1, 140.2, 134.6, 128.8, 123.6, 60.9.

MS: m/z (%) = 359 (100) [M + H]+.

IR: 1680, 1725 (C=O), 3346 (NH) cm–1.

Anal. Calcd for С6H2BrClIN3: C, 20.11; H, 0.56; N, 11.73. Found: C, 20.25; H, 0.44; N, 11.58.


#

Synthesis of Aminals 3; General Procedure

A 15 mL flask was charged with silylformamidine 1 (1 g, 6.3 mmol) and pyrazolo[1,5-a]pyrazine 2 (2 mmol). The mixture was stirred on a water bath (70–90 °C) until a homogeneous solution was formed. Excess silylformamidine 1 was distilled off (a water bath up to 90 °C; 0.1 Torr). The residue was dissolved in hexane (30 mL) under heating. It can be treated with activated carbon at r.t.. After cooling to r.t., the solution was filtered from impurities. The filtrate was evaporated to dryness, then the residue was dissolved in pentane (5 mL) and left to crystallize at –10 °C. The precipitated crystals were filtered, washed with cold pentane (25 mL), and dried.


#

1-(4-Chloropyrazolo[1,5-a]pyrazin-7-yl)-N,N,N′-trimethyl-N′-(tri­methylsilyl)methanediamine (3a)

A mixture of silylformamidine 1 (1 g, 6.3 mmol) and 4-chloropyrazolo[1,5-a]pyrazine 2a (3.07 g, 2 mmol) was stirred at r.t. for 4 days. Excess silylformamidine 1 was distilled off to give compound 3a.

Yield: 93% (1.89 g); slightly yellow crystals; mp 60–62 °C.

1H NMR (400 MHz, C6D6): δ = 7.97 (s, 1 H), 7.64 (s, 1 H), 6.49 (s, 1 H), 5.09 (s, 1 H), 2.02 (s, 9 H), 0.17 (s, 9 H).

13C NMR (150 MHz, C6D6): δ = 142.3, 141.0, 134.8, 131.7, 126.8, 132.4, 99.6, 74.9, 41.6, 26.9, –0.6.

Anal. Calcd for C13H22ClN5Si: C, 50.06; H, 7.11; N, 22.45. Found: C, 50.09; H, 6.87; N, 22.32.


#

1-(4-Methoxypyrazolo[1,5-a]pyrazin-7-yl)-N,N,N′-trimethyl-N-(trimethylsilyl)methanediamine (3b)

Yield: 58 % (1.2 g); white crystals; mp 62–63 °C; bp 122–125 °C / 0.1 Torr.

1H NMR (400 MHz, C6D6): δ = 7.84 (s, 1 H), 7.73 (s, 1 H), 6.69 (s, 1 H), 5.19 (s, 1 H), 3.83 (s, 3 H), 2.19 (s, 3 H), 2.15 (s, 6 H), 0.24 (s, 9 H).

13C NMR (125 MHz, C6D6): δ = 155.3, 139.5, 128.4, 126.5, 124.5, 97.7, 74.6, 52.6, 41.6, 26.6, –0.8.

Anal. Calcd for C14H25N5OSi: C, 54.69; H, 8.20; N, 22.78. Found: C, 54.76; H, 8.31; N, 22.65.


#

Methyl 7-((Dimethylamino)(methyl(trimethylsilyl)amino)methyl)pyrazolo[1,5-a]pyrazine-4-carboxylate (3c)

A mixture of methyl carboxylate 2c (1 g, 5.6 mmol) and silylformamidine 1 (1.7 g, 11 mmol) was heated at 90 °C for 30 min. Excess silylformamidine 1 was evaporated under a reduced pressure. The residue was recrystallized from hexane. The solution was left at –10 °C to afford aminal 3c.

Yield: 71% (1.22 g); yellow crystals; mp 117–118 °C.

1H NMR (400 MHz, C6D6): δ = 8.40 (s, 1 H), 7.83 (s, 1 H), 7.44 (s, 1 H), 5.22 (s, 1 H), 3.58 (s, 3 H), 2.06 (s, 3 H), 2.03 (s, 6 H), 0.17 (s, 9 H).

13C NMR (150 MHz, C6D6): δ = 164.1, 152.7, 142.1, 140.5, 135.6, 135.1, 101.0, 75.1, 51.8, 41.5, 27.0, –0.6.

Anal. Calcd for C15H25N5O2Si: C, 53.70; H, 7.51; N, 20.88. Found: C, 53.63; H, 7.32; N, 21.10.


#

7-((Dimethylamino)(methyl(trimethylsilyl)amino)methyl)pyrazolo[1,5-a]pyrazine-4-carbonitrile (3d)

Nitrile 2d (1 g, 7 mmol) and silylformamidine 1 (2.2 g, 14 mmol) were mixed and stirred at r.t. for 20 h. The reaction mixture turned dark brown. Excess silylformamidine was evaporated under a reduced pressure. The residue was treated with activated charcoal in pentane and recrystallized from pentane. The solution was left at –20 °C to afford aminal 3d.

Yield: 50% (1.06 g); yellow crystals; mp 72–73 °C.

1H NMR (400 MHz, C6D6): δ = 8.16 (s, 1 H), 7.55 (s, 1 H), 6.40 (s, 1 H), 5.06 (s, 1 H), 1.96 (s, 9 H), 0.14 (s, 9 H).

13C NMR (150 MHz, C6D6): δ = 141.9, 136.1, 135.4, 127.9, 126.0, 114.6, 98.0, 74.5, 41.0, 26.6, –0.9.

Anal. Calcd for C14H22N6Si: C, 55.60; H, 7.33; N, 27.79. Found: C, 55.78; H, 7.349; N, 27.68.


#

Methyl 3-(Difluoromethyl)-7-((dimethylamino)(methyl(trimethyl-silyl)amino)methyl)pyrazolo[1,5-a]pyrazine-4-carboxylate (3e)

A mixture of compound 2e (1 g, 4.4 mmol) and silylformamidine 1 (2.1 g, 13.3 mmol) was heated at 60 °C for 15 min. After cooling to r.t., excess silylformamidine was removed under reduced pressure to afford aminal 3e.

Yield: 88% (580 mg); viscous yellow oil.

1H NMR (400 MHz, C6D6): δ = 8.38 (s, 1 H), 8.20 (s, 1 H), 7.67 (t, J = 57 Hz, 1 H), 5.11 (s, 1 H), 3.52 (s, 3 H), 1.99 (s, 9 H), 0.13 (s, 9 H).


#

Methyl 3-Bromo-7-((dimethylamino)(methyl(trimethylsilyl)amino)methyl)pyrazolo[1,5-a]pyrazine-4-carboxylate (3f)

A mixture of compound 2f (1 g, 4 mmol) and silylformamidine 1 (1.9 g, 12 mmol) was stirred at r.t. for 20 h. After removal of excess silylformamidine under reduced pressure, the residue was recrystallized from pentane to afford aminal 3f.

Yield: 90% (1.45 g); yellowish solid; mp 113–114 °C.

1H NMR (400 MHz, C6D6): δ = 8.26 (s, 1 H), 7.64 (s, 1 H), 5.02 (s, 1 H), 3.61 (s, 3 H), 1.97 (s, 6 H), 1.94 (s, 3 H), 0.11 (s, 9 H).

13C NMR (125 MHz, C6D6): δ = 163.5, 143.5, 142.4, 142.1, 133.7, 130.6, 86.1, 74.3, 51.7, 41.1, 26.6, –0.9.

Anal. Calcd for C15H24BrN5O2Si: C, 43.48; H, 5.84; N, 16.90. Found: C, 43.73; H, 5.56; N, 17.12.


#

Methyl 7-((Dimethylamino)(methyl(trimethylsilyl)amino)methyl)-3-nitropyrazolo[1,5-a]pyrazine-4-carboxylate (3g)

A mixture of compound 2g (1 g, 4.5 mmol) and silylformamidine 1 (2.13 g, 13.5 mmol) in benzene (7 mL) was stirred at r.t. for 30 min, and then at 50 °C for 10 min. After removal of excess silylformamidine under reduced pressure, the residue was recrystallized from hexane to afford aminal 3g.

Yield: 77% (1.32 g); yellow crystals; mp 145–147 °C.

1H NMR (400 MHz, C6D6): δ = 8.39 (s, 1 H), 7.95 (s, 1 H), 4.88 (s, 1 H), 3.69 (s, 3 H), 1.91 (s, 6 H), 1.83 (s, 3 H), 0.06 (s, 9 H).

13C NMR (125 MHz, C6D6): δ = 163.9, 150.8, 144.6, 139.4, 134.3, 127.1, 74.7, 52.4, 48.3, 41.3, 26.8, –0.7.

Anal. Calcd for C15H24N6O4Si: C, 47.35; H, 6.36; N, 22.09. Found: C, 47.62; H, 6.29; N, 21.89.


#

Dimethyl 7-((Dimethylamino)(methyl(trimethylsilyl)amino)methyl)pyrazolo[1,5-a]pyrazine-3,4-dicarboxylate (3h)

A mixture of compound 2h (1 g, 4.3 mmol) and silylformamidine 1 (2.06 g, 13 mmol) was stirred at r.t. for 24 h. After removal of excess silylformamidine under reduced pressure, the residue was recrystallized from pentane to afford aminal 3h.

Yield: 71% (1.19 g); yellowish crystals; mp 102–103 °C.

1H NMR (400 MHz, C6D6): δ = 8.38 (s, 1 H), 8.28 (s, 1 H), 5.05 (s, 1 H), 3.80 (s, 3 H), 3.46 (s, 3 H), 1.96 (s, 6 H), 1.91 (s, 3 H), 0.11 (s, 9 H).

13C NMR (150 MHz, C6D6): δ = 164.8, 161.7, 145.8, 144.1, 134.0, 132.4, 129.6, 106.1, 75.0, 52.2, 50.9, 41.4, 26.8, –0.6.

Anal. Calcd for C17H27N5O4Si: C, 51.89; H, 6.92; N, 17.80. Found: C, 51.97; H, 6.87; N, 17.97.


#

1-(2-Bromo-4-chloro-3-iodopyrazolo[1,5-a]pyrazin-7-yl)-N,N,N′-trimethyl-N′-(trimethylsilyl)methanediamine (3i)

A mixture of compound 2i (1 g, 2.8 mmol) and silylformamidine 1 (1.33 g, 8.4 mmol) was heated to 80 °C for 15 min, kept at this temperature for 5 min, then cooled to r.t. After removal of excess silylformamidine under reduced pressure, the residue was recrystallized from hexane to afford aminal 3i.

Yield: 82% (1.18 g); yellow crystals; mp 122–124 °C.

1H NMR (400 MHz, C6D6): δ = 7.86 (s, 1 H), 4.81 (s, 1 H), 2.0 (s, 6 H), 1.92 (s, 3 H), 0.16 (s, 9 H).

13C NMR (150 MHz, C6D6): δ = 140.9, 139.3, 134.5, 132.1, 127.4, 74.8, 57.9, 41.6, 26.9, –0.7.

Anal. Calcd for C13H20BrClIN5Si: C, 30.22; H, 3.90; N, 13.55. Found: C, 29.87; H, 3.750; N, 13.24.


#

Synthesis of Aldehydes 4; General Procedure

Aminal 3 (3 mmol) was dissolved in aqueous 15% hydrochloric acid (2 mL). The reaction mixture was heated at 60 °C for 10 min with stirring. After cooling to r.t., the reaction mixture was extracted with dichloromethane (2 × 5 mL). The aqueous layer was separated, evaporated to dryness, washed with water (2 × 5 mL), and dried.


#

4-Oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-7-carbaldehyde (4a)

Yield: 93% (460 mg); colorless crystals; mp 255–258 °C.

1H NMR (600 MHz, DMSO-d 6): δ = 12.12 (s, 1 H, NH), 9.88 (s, 1 H), 7.98 (s, 1 H), 7.81 (s, 1 H), 7.11 (s, 1 H).

13C NMR (150 MHz, DMSO-d 6): δ = 181.0, 155.3, 141.0, 132.8, 129.7, 120.2, 105.4.

Anal. Calcd for C7H5N3O2: C, 51.54; H, 3.09; N, 25.76. Found: C, 51.76; H, 2.89; N, 25.86.


#

Methyl 7-Formylpyrazolo[1,5-a]pyrazine-4-carboxylate (4c)

Yield: 83% (504 mg); yellow crystals; mp 161–163 °C.

1H NMR (400 MHz, DMSO-d 6): δ = 10.68 (s, 0.3 H), 8.53, 8.44 (2 × s, 0.68 H), 8.33, 8.28 (2 × s 1.08 H), 7.45 (s, 0.39 H), 7.31 (s, 0.63 H), 7.12 (s, 0.69 H), 6.52 (s, 0.58 H), 4.01, 3.98 (2 × s, 3 H).

13C NMR (150 MHz, DMSO-d 6): δ = 184.5, 163.3, 162.7, 144.7, 143.7, 143.1, 140.4, 137.8, 135.0, 134.3, 130.6, 127.9, 124.6, 102.2, 100.6, 84.3, 53.1, 52.7.

Anal. Calcd for C9H7N3O3: C, 52.69; H, 3.44; N, 20.48. Found: C, 52.54; H, 3.65; N, 20.23.


#

Methyl 3-(Difluoromethyl)-7-formylpyrazolo[1,5-a]pyrazine-4-carboxylate (4e)

Yield: 87% (671 mg); yellow crystals; mp 147–149 °C.

1H NMR (400 MHz, DMSO-d 6): δ = 10.7 (s, 0.8 H), 8.71 (s, 0.8 H), 8.60 (s, 1.8 H), 8.31 (s, 1 H), 7.51 (t, J = 56 Hz, 1 H), 7.2 (bs, 1.4 H), 6.51 (s, 1 H), 4.0 (s, 3 H).

13C NMR (150 MHz, DMSO-d 6): δ = 184.3, 163.9, 163.4, 145.5, 142.3, 141.8, 141.3, 138.2, 131.5, 131.1, 130.6, 128.1, 125.7, 113.2, 113.0, 11.7, 111.4, 110.1, 109.9, 109.7, 109.5, 108.6, 108.4, 108.2, 53.5, 53.2.

Anal. Calcd for C10H7F2N3O3: C, 47.07; H, 2.77; N, 16.47. Found: C, 47.32; H, 2.87; N, 16.87.


#

Methyl 3-Bromo-7-formylpyrazolo[1,5-a]pyrazine-4-carboxylate (4f)

Aminal 3f (1.23 g, 3 mmol) was dissolved in aqueous 20% hydrobromic acid (2 mL). The reaction mixture was heated at 60 °C for 10 min with stirring. After cooling to r.t., the reaction mixture was extracted with dichloromethane (3 × 10 mL), then all volatiles were evaporated and the residue was dissolved in diethyl ether (20 mL) upon heating. The solution was filtered and the volume was reduced to 1 mL and left for crystallization. The precipitated aldehyde was collected and dried.

Yield: 52% (440 mg); yellow crystals; mp 115–116 °C.

1H NMR (400 MHz, CDCl3): δ = 10.84 (s, 1 H), 8.50 (s, 1 H), 8.23 (s, 1 H), 4.13 (s, 3 H).

13C NMR (150 MHz, CDCl3): δ = 183.0, 162.8, 148.9, 144.9, 131.4, 131.1, 127.5, 89.7, 53.6.

Anal. Calcd for C9H6BrN3O3: C, 38.05; H, 2.13; N, 14.79. Found: C, 37.88; H, 1.98; N, 14.97.

HRMS (ESI): m/z [M + H]+ calcd for C9H6BrN3O3: 283.9671; found: 283.9665.


#

Methyl 7-Formyl-3-nitropyrazolo[1,5-a]pyrazine-4-carboxylate (4g)

Yield: 80% (605 mg); yellow crystals; mp 150–151 °C (diethyl ether).

1H NMR (400 MHz, CDCl3): δ = 10.94 (s, 1 H), 8.84 (s, 1 H), 8.77 (s, 1 H), 4.11 (s, 3 H).

13C NMR (150 MHz, CDCl3): δ = 181.6, 162.6, 149.2, 140.5, 132.6, 127.8, 126.2, 125.9, 53.4.

Anal. Calcd for C9H6N4O5: C, 43.21; H, 2.42; N, 22.40. Found: C, 43.43; H, 2.34; N, 22.34.


#

Dimethyl 7-Formylpyrazolo[1,5-a]pyrazine-3,4-dicarboxylate (4h)

Yield: 51% (400 mg); yellow crystals; mp 118–120 °C.

1H NMR (400 MHz, CDCl3): δ = 10.90 (s, 1 H), 8.63 (s, 1 H), 8.60 (s, 1 H), 4.10 (s, 3 H), 3.95 (s, 3 H).

13C NMR (125 MHz, CDCl3): δ = 182.7, 163.5, 161.2, 150.3, 145.2, 131.7, 131.5, 126.6, 107.7, 53.1, 51.8.

Anal. Calcd for C11H9N3O5: C, 50.20; H, 3.45; N, 15.96. Found: C, 50.34; H, 3.61; N, 16.11.

HRMS (ESI): m/z [M + H]+ calcd for C11H9N3O5: 264.0621; found: 264.0616.


#

Synthesis of Methylimines; General Procedure

Aminal 3 (3 mmol) was dissolved in MeOH (20 mL) at 30 °C. After 30 min, the volume was reduced to 5 mL and the reaction mixture was left at –10 °C. The precipitated solid was collected by filtration, washed with cold MeOH (2 × 5 mL) and dried.


#

(E)-N-((4-Methoxypyrazolo[1,5-a]pyrazin-7-yl)methylene)methanamine (5b)

Aminal 3b (0.7 g, 2.3 mmol) was dissolved in MeOH (10 mL). The reaction mixture was heated at 40 °C for 1 h. The solvent was evaporated and the residue was sublimated (0.1 Torr, oil bath at 130 °C).

Yield: 90% (387 mg); white solid; mp 116–118 °C.

1H NMR (400 MHz, CDCl3): δ = 8.88 (s, 1 H), 7.91 (s, 1 H), 7.86 (s, 1 H), 6.78 (s, 1 H), 4.07 (s, 3 H), 3.58 (s, 3 H).

13C NMR (125 MHz, CDCl3): δ = 157.0, 152.8, 140.3, 127.6, 125.9, 124.5, 98.3, 53.6, 48.5.

Anal. Calcd for C9H10N4O: C, 56.83; H, 5.30; N, 29.46. Found: C, 56.98; H, 5.67; N, 29.12.


#

Methyl (Z)-7-((Methylimino)methyl)-3-nitropyrazolo[1,5-a]pyrazine-4-carboxylate (5g)

Aminal 3g (3 mmol) was dissolved in MeOH (20 mL) and heated at 60 °C for 30 min. The solution was then cooled to –20 °C and the precipitated solid was collected by filtration, washed with cold MeOH (2 × 5 mL), and dried.

Yield: 75% (600 mg); yellow crystals; mp 152–153 °C.

1H NMR (400 MHz, CDCl3): δ = 9.18 (s, 1 H), 8.83 (s, 1 H), 8.76 (s, 1 H), 4.08 (s, 3 H), 3.78 (s, 3 H).

13C NMR (125 MHz, CDCl3): δ = 163.3, 150.8, 145.5, 140.1, 129.9, 129.1, 126.8, 126.2, 53.2, 49.0.

Anal. Calcd for C10H9N5O4: C, 45.63; H, 3.45; N, 26.61. Found: C, 45.37; H, 3.63; N, 26.34.


#

1-(2-Bromo-4-chloro-3-iodopyrazolo[1,5-a]pyrazin-7-yl)-N-meth­ylmethanimine (5i)

Aminal 3i (1.53 g, 3 mmol) was dissolved in MeOH (20 mL) and heated at 35 °C for 30 min. The volume was reduced to a half then the solution was cooled to –10 °C. The precipitated solid was collected by filtration, washed with cold MeOH (2 × 5 mL), and dried.

Yield: 68% (810 mg); yellow crystals; mp 187–189 °C.

1H NMR (400 MHz, DMSO-d 6): δ = 8.90 (s, 1 H), 8.10 (s, 1 H), 3.61 (s, 3 H).

13C NMR (125 MHz, DMSO-d 6): δ = 152.3, 142.5, 139.9, 134.1, 128.7, 126.0, 61.9, 48.2.

Anal. Calcd for C8H5BrClIN4: C, 24.06; H, 1.26; N, 14.03. Found: C, 23.69; H, 1.02; N, 13.78.


#

7-((2-Phenylhydrazono)methyl)pyrazolo[1,5-a]pyrazin-4(5H)-one (6a)

Aldehyde 4a (50 mg, 0.3 mmol) was dissolved in MeOH (3 mL) and phenylhydrazine (65 mg, 0.6 mmol) was added and the reaction mixture was heated at 60 °C for 5 min. After cooling to r.t., the precipitated solid was collected by filtration, and dried.

Yield: 72% (56 mg); yellow crystals; mp 264–266 °C (decomp).

1H NMR (500 MHz, DMSO-d 6): δ = 11.55 (s, 1 H, NH), 10.64 (s, 1 H), 8.35 (s, 1 H), 7.98 (s, 1 H), 7.27 (s, 1 H), 7.22 (dd, J = 8, 8 Hz, 2 H), 7.08 (m, 3 H), 6.70 (dd, J = 8, 8 Hz, 1 H).

13C NMR (125 MHz, DMSO-d 6): δ = 154.9, 144.8, 140.3, 133.2, 129.1, 126.4, 119.2, 118.8, 112.1, 111.4, 105.0.

Anal. Calcd for C13H11N5O: C, 61.65; H, 4.38; N, 27.65. Found: C, 61.78; H, 4.12; N, 27.45.

HRMS (ESI): m/z [M + H]+ calcd for C13H11N5O: 254.1042; found: 254.10391.


#
#

Conflict of Interest

The authors declare no conflict of interest.

Supporting Information

  • References

  • 1 Abd ul-MalikM. A, Zaki RM, Kamal El-Dean AM, Radwan SM. J. Heterocycl. Chem. 2018; 55: 1828
  • 2 Zheng L.-W, Shao J.-H, Zhao B.-X, Miao J.-Y. Bioorg. Med. Chem. Lett. 2011; 21: 3909
  • 3 González SM, Hernández AI, Álvarez RM, Rodríguez A, Ramos-Lima F, Bischoff JR, Albarrán MI, Cebriá A, Hernández-Encinas E, García-Arocha J, Cebrián D, Blanco-Aparicio C, Pastor J. Bioorg. Med. Chem. Lett. 2017; 27: 4794
  • 4 Pastor Fernández J, Martínez Gonzáles S, Rodriguéz Hergueta A, Ramos Lima FJ, Alvarez Escobar RM, Higueras Hernández AI. WO 2011/141713, 2011
  • 5 Ninkovic S, Braganza JF, Collins MR, Kath JC, Li H, Richter DT. WO 2010/016005, 2010
  • 6 Gray DL. F, Davoren JE, Dounay AB, Efremov IV, Mente SR, Subramanyam C. WO 2015/166370, 2017
  • 7 Arban R, Bianchi F, Buson A, Cremonesi S, Di Fabio R, Gentile G, Micheli F, Pasquarello A, Pozzan A, Tarsi L, Terreni S, Tonelli F. Bioorg. Med. Chem. Lett. 2010; 20: 5044
  • 8 Askew BC, McIntyre CJ, Hunt CA, Claremon DA, Gould RJ, Lynch RJ, Armstrong DJ. Bioorg. Med. Chem. Lett. 1995; 5: 475
  • 9 Woll MG, Qi H, Turpoff A, Zhang N, Zhang X, Chen G, Li C, Huang S, Yang T, Moon Y.-C, Lee C.-S, Choi S, Almstead NG, Naryshkin NA, Dakka A, Narasimhan J, Gabbeta V, Welch E, Zhao X, Risher N, Sheedy J, Weetall M, Karp GM. J. Med. Chem. 2016; 59: 6070
  • 10 Liverton N, Kuduk SD, Beshore DC, Meng N, Luo Y. WO 2016/101119, 2016
  • 11 Shen S.-L, Zheng L.-W, Wang S.-Q, Zhang Y.-R, Zhang Y, Liu YR, Zhao B.-X. ARKIVOC 2013; (iv): 44
  • 12 Xie Y.-S, Pan X.-H, Zhao B.-X, Liu J.-T, Shin D.-S, Zhang J.-H, Zheng L.-W, Zhao J, Miao J.-Y. J. Organomet. Chem. 2008; 693: 1367
  • 13 Zhang J.-H, Fan C.-D, Zhao B.-X, Shin D.-S, Dong W.-L, Xie Y.-S, Miao J.-Y. Bioorg. Med. Chem. 2008; 16: 10165
  • 14 Pan X.-H, Liu X, Zhao B.-X, Xie Y.-S, Shin D.-S, Zhang S.-L, Zhao J, Miao J.-Y. Bioorg. Med. Chem. 2008; 16: 9093
    • 15a Marchenko A, Koidan G, Hurieva A, Shvydenko K, Rozhenko AB, Rusanov EB, Kyrylchuk AA, Kostyuk A. J. Org. Chem. 2022; 87: 373
    • 15b Koidan G, Hurieva A, Zahorulko S, Zadorozhny A, Lysenko V, Shvydenko T, Rusanov EB, Kostyuk A. Eur. J. Org. Chem. 2022; 101
    • 15c Koidan G, Zahorulko S, Hurieva A, Shvydenko T, Rusanov EB, Rozhenko AB, Manthe U, Kostyuk A. Chem. Eur. J. 2023; e202301675
  • 16 Roszak R, Beker W, Molga K, Grzybowski BA. J. Am. Chem. Soc. 2019; 141 (43) 17142
  • 17 Abdul-Malik MA, Zaki RM, El-Dean AM. K, Radwan SM. J. Heterocycl. Chem. 2018; 55: 1828

Corresponding Author

Aleksandr Kostyuk
Institute of Organic Chemistry, National Academy of Sciences of Ukraine
Academician Kukhar str., 5, Kyiv-94, 02660
Ukraine   

Publication History

Received: 18 March 2024

Accepted after revision: 22 May 2024

Article published online:
01 July 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Abd ul-MalikM. A, Zaki RM, Kamal El-Dean AM, Radwan SM. J. Heterocycl. Chem. 2018; 55: 1828
  • 2 Zheng L.-W, Shao J.-H, Zhao B.-X, Miao J.-Y. Bioorg. Med. Chem. Lett. 2011; 21: 3909
  • 3 González SM, Hernández AI, Álvarez RM, Rodríguez A, Ramos-Lima F, Bischoff JR, Albarrán MI, Cebriá A, Hernández-Encinas E, García-Arocha J, Cebrián D, Blanco-Aparicio C, Pastor J. Bioorg. Med. Chem. Lett. 2017; 27: 4794
  • 4 Pastor Fernández J, Martínez Gonzáles S, Rodriguéz Hergueta A, Ramos Lima FJ, Alvarez Escobar RM, Higueras Hernández AI. WO 2011/141713, 2011
  • 5 Ninkovic S, Braganza JF, Collins MR, Kath JC, Li H, Richter DT. WO 2010/016005, 2010
  • 6 Gray DL. F, Davoren JE, Dounay AB, Efremov IV, Mente SR, Subramanyam C. WO 2015/166370, 2017
  • 7 Arban R, Bianchi F, Buson A, Cremonesi S, Di Fabio R, Gentile G, Micheli F, Pasquarello A, Pozzan A, Tarsi L, Terreni S, Tonelli F. Bioorg. Med. Chem. Lett. 2010; 20: 5044
  • 8 Askew BC, McIntyre CJ, Hunt CA, Claremon DA, Gould RJ, Lynch RJ, Armstrong DJ. Bioorg. Med. Chem. Lett. 1995; 5: 475
  • 9 Woll MG, Qi H, Turpoff A, Zhang N, Zhang X, Chen G, Li C, Huang S, Yang T, Moon Y.-C, Lee C.-S, Choi S, Almstead NG, Naryshkin NA, Dakka A, Narasimhan J, Gabbeta V, Welch E, Zhao X, Risher N, Sheedy J, Weetall M, Karp GM. J. Med. Chem. 2016; 59: 6070
  • 10 Liverton N, Kuduk SD, Beshore DC, Meng N, Luo Y. WO 2016/101119, 2016
  • 11 Shen S.-L, Zheng L.-W, Wang S.-Q, Zhang Y.-R, Zhang Y, Liu YR, Zhao B.-X. ARKIVOC 2013; (iv): 44
  • 12 Xie Y.-S, Pan X.-H, Zhao B.-X, Liu J.-T, Shin D.-S, Zhang J.-H, Zheng L.-W, Zhao J, Miao J.-Y. J. Organomet. Chem. 2008; 693: 1367
  • 13 Zhang J.-H, Fan C.-D, Zhao B.-X, Shin D.-S, Dong W.-L, Xie Y.-S, Miao J.-Y. Bioorg. Med. Chem. 2008; 16: 10165
  • 14 Pan X.-H, Liu X, Zhao B.-X, Xie Y.-S, Shin D.-S, Zhang S.-L, Zhao J, Miao J.-Y. Bioorg. Med. Chem. 2008; 16: 9093
    • 15a Marchenko A, Koidan G, Hurieva A, Shvydenko K, Rozhenko AB, Rusanov EB, Kyrylchuk AA, Kostyuk A. J. Org. Chem. 2022; 87: 373
    • 15b Koidan G, Hurieva A, Zahorulko S, Zadorozhny A, Lysenko V, Shvydenko T, Rusanov EB, Kostyuk A. Eur. J. Org. Chem. 2022; 101
    • 15c Koidan G, Zahorulko S, Hurieva A, Shvydenko T, Rusanov EB, Rozhenko AB, Manthe U, Kostyuk A. Chem. Eur. J. 2023; e202301675
  • 16 Roszak R, Beker W, Molga K, Grzybowski BA. J. Am. Chem. Soc. 2019; 141 (43) 17142
  • 17 Abdul-Malik MA, Zaki RM, El-Dean AM. K, Radwan SM. J. Heterocycl. Chem. 2018; 55: 1828

Zoom Image
Scheme 1 N,N,N′,1,1,1-Hexamethylsilane-carboximidamide in equilibrium with the carbene form
Zoom Image
Figure 1 pK a values calculated for compounds 2ad in DMSO
Zoom Image
Scheme 2 Synthesis of the starting compounds 2
Zoom Image
Scheme 3 Synthesis of imines 5 and hydrazone 6a
Zoom Image
Figure 2 Molecular structure of 3f (left), 3g (middle), and 6a (right) according to X-ray diffraction data. Thermal ellipsoids are shown at 50% probability level